BPC-157: What the Evidence Actually Shows The honest summary of BPC-157 is a striking mismatch between its reputation and its evidence base
Note, in general, since the beginning, the concept of cytoprotection did not consider the neurotransmitter activity as the basis for the cytoprotective effects of the implemented agents (i.e., prostaglandins [16,17], sulfhydryl [141], somatostatin [142], dopamine [143])
Because we are a medical clinic, medically necessary treatment may be covered by plans such as Aetna, Cigna, Florida Blue, and Humana, and we are clear about self-pay costs upfront
For individuals with adequate baseline levels, results may be less pronounced
Pigmentation changes are rare but possible, particularly with higher doses or extended use
Here is what the published research actually looks at for each one